Drug Prices in Ads: Senate Passes Amendment image

RAPS Regulatory Focus, August 24, 2018
Zachary Brennan, quoting Rachel Sachs (Academic Fellow Alumna)


Read the full article

From the article: 

Earlier this month, CMS also announced plans to begin using what’s called step therapy to try to lower the spend on Part B drugs by about 20% in Medicare Advantage plans. The announcements are beginning to add up to a wider effort, including FDA’s generic drug approvals, to bring down the prices of pharmaceuticals. But whether the moves actually bring down prices remains to be seen.

Rachel Sachs, an assistant professor of law at Washington University in St. Louis, told Focus: “Secretary Azar has decried the use of political 'gimmicks' that wouldn’t have an effect on the problem, but the administration has not yet explained publicly how they think including prices in direct-to-consumer advertisements will lead to drug companies choosing to lower their prices.”

Read more here!

fda health law policy medicaremedicaid pharmaceuticals